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ABSTRACT Staphylococcus epidermidis has emerged as an important opportunistic
pathogen causing orthopedic-device-related infections (ODRI). This study investi-
gated the association of genome variation and phenotypic features of the infecting
S. epidermidis isolate with the clinical outcome for the infected patient. S. epidermidis
isolates were collected from 104 patients with ODRI. Their clinical outcomes were
evaluated, after an average of 26 months, as either “cured” or “not cured.” The iso-
lates were tested for antibiotic susceptibility and bioﬁlm formation. Whole-genome
sequencing was performed on all isolates, and genomic variation was related to fea-
tures associated with “cured” and “not cured.” Strong bioﬁlm formation and amin-
oglycoside resistance were associated with a “not-cured” outcome (P  0.031 and
P  0.001, respectively). Based on gene-by-gene analysis, some accessory genes
were more prevalent in isolates from the “not-cured” group. These included the
bioﬁlm-associated bhp gene, the antiseptic resistance qacA gene, the cassette
chromosome recombinase-encoding genes ccrA and ccrB, and the IS256-like
transposase gene. This study identiﬁes bioﬁlm formation and antibiotic resistance
as associated with poor outcome in S. epidermidis ODRI. Whole-genome sequenc-
ing identiﬁed speciﬁc genes associated with a “not-cured” outcome that should
be validated in future studies. (The study has been registered at ClinicalTrials.gov
with identiﬁer NCT02640937.)
KEYWORDS Staphylococcus epidermidis, MRSE, virulence factors, antibiotic resistance,
genotype, phenotype, orthopedic-device-related infections
Staphylococcus epidermidis is a common member of the human skin microﬂora,predominant in moist sites such as nares or fossae and in sebaceous areas such as
the facial skin. With the advent of implanted and indwelling medical devices, S.
epidermidis has emerged as a prominent cause of nosocomial and device-associated
infections (1, 2). The microorganism’s ability to switch from a commensal to pathogenic
lifestyle is facilitated by its ability to rapidly attach to, and form bioﬁlms upon, medical
devices. In the case of orthopedic-device-related infections (ODRI), S. epidermidis ac-
counts for up to 43% of cases and is second only to Staphylococcus aureus as the most
prevalent causative organism (1, 2).
Molecular epidemiological studies have begun to reveal information on both the
population structure and genetic diversity within S. epidermidis populations (3–5). The
complete S. epidermidis genome is estimated at approximately 2.5 Mb and comprises
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80% core genes and 20% variable genes (3, 4, 6). Three distinct phylogenetic groups
(clades) are evident in the population structure of S. epidermidis (3, 4, 6), with at least
nine globally disseminated clonal complex (CC) lineages. The most common clonal
complex (CC2) contains one particularly prominent sequence type (ST), ST2 (32% of all
isolates) (5, 7).
In an attempt to identify the features that enable invasive infection in S. epidermidis,
a number of studies have searched for features that may distinguish invasive from
commensal S. epidermidis isolates on genotypic and phenotypic levels. Such studies
have identiﬁed features such as IS256, the folate dehydrogenase gene, and copper
remediation genes to be more common among invasive isolates (3, 6, 8, 9). However,
clear separation between the two has proven to be difﬁcult (9–11), perhaps indicating
that the ability to invade the host and the ability to colonize it do not require
signiﬁcantly different genetically encoded features. One possibility, which has not been
explored to date, however, is whether the genome/phenotype of the invasive isolate
dictates the ultimate course of an infection, i.e., whether the patient eventually has a
successful treatment outcome or a failed treatment outcome.
In the present study, S. epidermidis isolates were prospectively collected from
patients with ODRI and were assigned a clinical outcome (either “cured” or “not cured”)
after an extended patient follow-up (FUP). Clinical outcome was then related to
genome variation and phenotypes believed to be important for S. epidermidis virulence.
RESULTS
Patient outcome and clinical parameters. A total of 104 patients with S. epider-
midis ODRI were included in this study; complete demographic information is shown in
Table 1. The lower-extremity cohort (70 patients) included only those patients with
infection of the hip, knee, and upper ankle joints as well as the femur, tibia, and ﬁbula.
The majority of patients of the complete cohort study (n  85, 81.7%) were considered
to have had a “cured” clinical outcome at FUP.
Those considered to have a “not-cured” clinical outcome at FUP were statistically
more likely to have had multiple revision surgeries in comparison with those with
“cured” outcome isolates (P  0.067) (Table 2). There was no association between
outcome and any of the other monitored parameters, such as diabetes, chronic
immunosuppression, or obesity (Table 2).
Patient outcome and phenotypic properties of isolates. (i) Antibiotic suscepti-
bility. Antibiotic susceptibility testing of the 104 S. epidermidis isolates found that 74%
(77/104) were multiply resistant isolates and 67.3% (70/104) were resistant to methi-
cillin (Table 1). Rifampin resistance was also observed in 19.2% (20/104) of the isolates,
which is notable due to the critical role of this antibiotic in treating ODRI. Resistance to
aminoglycosides had a statistically signiﬁcant inﬂuence on a “not-cured” clinical out-
come (P  0.001) (Table 3). Further antibiotic resistance (including resistance to
aminoglycosides) had no statistically signiﬁcant inﬂuence on any of the other prog-
nostic parameters, such as chronic or acute ODRI. Although isolates from the group of
chronic ODRI were more often resistant to aminoglycosides than isolates from the
acute-ODRI group (42.7% of versus 31%), this was not statistically signiﬁcant (P 
0.276). Furthermore, multidrug resistance also showed no statistically signiﬁcant differ-
ence between chronic and acute ODRI (73.3% versus 75.9%).
(ii) Bioﬁlm formation. As shown in Table 1, 70.2% (73/104) of the isolates formed
a bioﬁlm in vitro. The ability to form bioﬁlm was subdivided into weak bioﬁlm formers
(37.5% [39/104] of the isolates), intermediate bioﬁlm formers (21.2%, 22/104), and
strong bioﬁlm formers (11.5%, 12/104). The remaining isolates (29.8%, 31/104) were
unable to form a bioﬁlm under our in vitro conditions. A statistically signiﬁcant
association between bioﬁlm-forming ability and clinical “cured” versus “not-cured”
outcome was noted for the lower-extremity cohort (P  0.031) (Table 3). Strong
bioﬁlm-forming ability also resulted in the highest percentage of “not-cured” outcome
for the complete cohort (33.3%, P  0.059) (Table 3). However, the strength of bioﬁlm
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formation had no statistically signiﬁcant inﬂuence on any of the prognostic variables,
such as multiple revision surgery.
A description of bioﬁlm-associated genes and their relative presence with respect to
in vitro bioﬁlm-forming ability is shown in Table 4. Among strongly bioﬁlm-forming
isolates, the intercellular adhesion (icaA) gene was more prevalent (83.3%) than the
accumulation-associated protein-encoding aap gene (8.3%), the bhp (cell wall-
associated bioﬁlm protein) gene (16.7%), and the embP (extracellular matrix-binding
protein) gene (66.7%).
TABLE 1 Patient health status, infection characteristics, bacteriology, clinical course, and
outcome
Parameter
No. (%) of patients
Complete study
cohort
Lower-extremity
cohort
Totala 104 (100.0) 70 (100.0)
Clinical course and infection outcome
Multiple revision surgeries 89 (85.6) 68 (97.1)
Clinical outcome, cured 85 (81.7) 53 (75.7)
Health status
Obesityb 44 (42.3) 32 (45.7)
Smoking 28 (26.9) 17 (24.3)
Diabetes 14 (13.5) 8 (11.4)
Chronic immunosuppression 25 (24.0) 14 (20.0)
Infection characteristics
Infection after fracture ﬁxation 78 (75.0) 44 (62.9)
Prosthetic joint infection 26 (25.0) 26 (37.1)
Acute infection 29 (27.9) 20 (28.6)
Closed fracturec 53 (67.9) 25 (56.8)
Open fracture 25 (32.1) 19 (43.2)
Type of implant
Internal ﬁxator 6 (5.8) 0 (0)
Prosthetic joint 26 (25.0) 26 (37.1)
Nail 23 (22.1) 20 (28.6)
Plate 40 (38.5) 22 (31.4)
Screw 8 (7.7) 2 (2.9)
K-wire 1 (1.0) 0 (0)
Localization
Spine 6 (5.8) NAd
Upper extremity 7 (6.7) NA
Pelvis 7 (6.7) NA
Tibia 2 (1.9) NA
Clavicle 3 (2.9) NA
Hip joint 10 (9.6) 10 (14.3)
Femur 7 (6.7) 7 (10.0)
Knee joint 18 (17.3) 18 (25.7)
Lower leg, including upper ankle joint 35 (33.7) 35 (50.0)
Lower ankle joint, including foot 9 (8.7) NA
Bacteriological evaluation
Methicillin resistance 70 (67.3) 52 (74.3)
Multidrug resistance 77 (74.0) 56 (80.0)
Bioﬁlm formation
None 31 (29.8) 24 (34.3)
Weak 39 (37.5) 26 (37.1)
Intermediate 22 (21.2) 11 (15.7)
Strong 12 (11.5) 9 (12.9)
aEach patient had 1 S. epidermidis isolate.
bDeﬁned as a BMI of 30.
cProsthetic joint infection not included.
dNA, not applicable.
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Patient outcome and pathogen genome variation. (i) Relationship between
virulence-associated genes and patient outcome. The 104 genomes were analyzed
for the presence of a selection of genes previously described as virulence factors in S.
epidermidis (Fig. 1) (12–14). Within the population as a whole (i.e., “cured” and “not-
cured” outcome isolates), aae (vitronectin), gehC (lipase), gehD (lipase), hlb (-
hemolysin), sesB (S. epidermidis surface protein), and sesC (S. epidermidis surface protein)
were present in all 104 isolates. The methicillin resistance gene mecA was carried by
68.3% of the isolates, whereby 69/70 of the phenotypically conﬁrmed methicillin-
resistant S. epidermidis (MRSE) isolates and 2/34 of the phenotypically conﬁrmed
methicillin-susceptible S. epidermidis (MSSE) isolates possessed this gene. Figure 1 also
shows the distribution of the known virulence genes between the 2 clinical outcome
groups (“cured” and “not cured”). A trend for the presence of aminoglycoside resistance
gene aacA [aac(6=)-aph(2) and mecA] in the “not-cured” outcome isolates (P  0.076
and P  0.099, respectively) was observed. In addition, the presence of bioﬁlm-
associated bhp was statistically signiﬁcantly associated with a “not-cured” clinical
outcome in the lower-extremity cohort (P  0.023).
(ii) agr types. Overall, accessory gene regulator (agr) type I was the most prevalent
type (38.5%, 40/104) among the isolates, followed by agr type III (36.5%, 38/104). The
distribution of the 3 different agr types within the “cured” and “not-cured” outcome
groups are shown in Table 5; however, there were no statistically signiﬁcant differences
TABLE 2 Association between prognostic factors and cure status for the complete study
cohort
Parameter
No. (%) of patients in:
Odds ratio for cureda
(95% conﬁdence
interval) P valueb
“Not-cured”
group
“Cured”
group
Total no. of patientsc 19 (18.3) 85 (81.7)
Infection type 0.92 (0.30;2.86) 1.000†
FFI 14 (17.9) 64 (82.1)
PJI 5 (19.2) 21 (80.8)
Fracture 0.39 (0.12;1.27) 0.126†
Closed 7 (13.2) 46 (86.8)
Open 7 (28.0) 18 (72.0)
Acute infection 1.56 (0.44;7.08) 0.463††
No 15 (20.0) 60 (80.0)
Yes 4 (13.8) 25 (86.2)
Multiple revision surgery 0.12 (0.00;2.04) 0.067†
No 0 (0.0) 15 (100.0)
Yes 19 (21.3) 70 (78.7)
Obesity 0.78 (0.25;2.42) 0.621††
No 10 (16.7) 50 (83.3)
Yes 9 (20.5) 35 (79.5)
Smoking 0.76 (0.23;2.74) 0.613††
No 13 (17.1) 63 (82.9)
Yes 6 (21.4) 22 (78.6)
Diabetes 0.50 (0.14;1.81) 0.281†
No 15 (16.7) 75 (83.3)
Yes 4 (28.6) 10 (71.4)
Chronic
immunosuppression
0.46 (0.16;1.34) 0.233†
No 12 (15.2) 67 (84.8)
Yes 7 (28.0) 18 (72.0)
aFor calculation of odds ratios involving cells with 0 observations, the 0.5 zero-cell correction was applied.
b†, chi-square test; ††, Fisher’s exact test.
cEach patient had 1 S. epidermidis isolate.
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(P  0.05). The only parameter associated with agr type was acute infection (Table 5).
All other clinical parameters were not statistically associated with agr type.
(iii) MLST. Within the 104 isolates, 21 different sequence types (STs) were identiﬁed
based on the 7-locus scheme for S. epidermidis (15) using the build-in multilocus
sequence typing (MLST) function of BIGSdb linked with PubMLST databases (4) (Table
6). Thirty isolates could not be assigned to any known ST. While the majority of the ST2
(13/18, 72.2%) and ST5 (16/18, 88.9%) isolates were associated with a “cured” outcome,
all ST57 (2/2, 100%), ST89 (1/1, 100%), and S110 (1/1, 100%) isolates were associated
with a “not-cured” outcome (Table 6). However, more isolates would be needed to
draw statistical conclusions. The identiﬁed STs belonged to previously described
7-locus MLST clonal complexes (CCs), of which the largest was CC2 (65/104, 62.5%)
(4) (Table 6).
Patient outcome and accessory genomes. Further evaluation of the relative
presence of accessory genes that were more prevalent in the “not-cured” outcome
group than in the “cured” outcome group is shown in Table 7. S. epidermidis isolates
from the “not-cured” outcome group carried the antiseptic resistance-coding gene
qacA at a statistically signiﬁcant higher percentage than isolates from the “cured”
outcome group (89.5% versus 27.1%; P  0.023). Furthermore, the presence of the
cassette chromosome recombinase-encoding genes ccrA and ccrB (89.5% versus 23.6%
and 89.5% versus 24.7%; P  0.042 and P  0.034, respectively) was signiﬁcantly
associated with the “not-cured” isolate genomes.
Core and accessory genome analysis. A pan-genome of all study isolates was used
to compare the genomes of the 104 clinical S. epidermidis isolates. ClonalFrame was
used to construct ancestral genealogies, free from recombination. In order to run
ClonalFrame, a stringent approach to selecting core genes based on presence in 100%
of the 104 isolates was applied. This resulted in a reduced core genome consisting of
TABLE 3 Association between bacterial phenotype and clinical cured status
Parameter
Complete cohort (n  104) Lower-extremity cohort (n  70)
No. (%) of patients in:
Odds ratio for cured
(95% conﬁdence
interval) P valuea
No. (%) of patients in:
Odds ratio for cured
(95% conﬁdence
interval) P valuea
“Not-cured”
group
“Cured”
group
“Not-cured”
group
“Cured”
group
Bioﬁlm formation 0.059††† 0.031†††
None 3 (9.7) 28 (90.3) 3 (12.5) 21 (87.5)
Weak 7 (17.9) 32 (82.1) 0.49 (0.08;2.43) 6 (23.1) 20 (76.9) 0.48 (0.07;2.64)
Intermediate 5 (22.7) 17 (77.3) 0.36 (0.05;2.19) 4 (36.4) 7 (63.6) 0.25 (0.03;1.96)
Strong 4 (33.3) 8 (66.7) 0.21 (0.03;1.62) 4 (44.4) 5 (55.6) 0.18 (0.02;1.51)
Antibiotic resistanceb
Methicillin 0.33 (0.06;1.29) 0.082†† 0.54 (0.14;2.16) 0.529†
No 3 (8.8) 31 (91.2) 3 (16.7) 15 (83.3)
Yes 16 (22.9) 54 (77.1) 14 (26.9) 38 (73.1)
Aminoglycosides 0.17 (0.04;0.56) .001†† 0.051††
No 5 (7.9) 58 (92.1) 5 (14.3) 30 (85.7) 0.32 (0.08;1.17)
Yes 14 (34.1) 27 (65.9) 12 (34.3) 23 (65.7)
a†, chi-square test; ††, Fisher’s exact test; †††, Cochran-Armitage trend test.
bNot all antibiotic resistances are listed. Others tested showed no statistical signiﬁcance.
TABLE 4 Bioﬁlm-associated genes and bioﬁlm formation
Bioﬁlm-associated
gene
No. (%) of isolates with gene and the indicated bioﬁlm strength in vitro
Complete cohort study (n  104) Lower-extremity cohort study (n  70)
None (n  31) Weak (n  39)
Intermediate
(n  22)
Strong
(n  12) None (n  24) Weak (n  26)
Intermediate
(n  11)
Strong
(n  9)
icaA 7 (22.6) 7 (18.0) 8 (36.4) 10 (83.3) 7 (29.2) 5 (19.2) 6 (54.5) 8 (88.9)
aap 1 (3.2) 0 (0) 0 (0) 1 (8.3) 1 (4.2) 0 (0) 0 (0) 0 (0)
bhp 7 (22.6) 10 (25.7) 0 (0) 2 (16.7) 4 (16.7) 9 (34.6) 0 (0) 1 (11.1)
embP 28 (90.3) 31 (79.5) 15 (68.2) 8 (66.7) 21 (87.5) 20 (76.9) 6 (54.5) 6 (66.7)
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123 nontruncated genes. S. epidermidis isolates clustered into 3 clades (Fig. 2), with 86%
of isolates (89/104) in clade A, 9.6% (10/104 isolates) in clade B, and 4.8% (5/104
isolates) in clade C (Fig. 2A).
Comparing patient outcome between the clades, a trend between clades A and B
was observed. Clade B consisted of a comparatively higher percentage of “not-cured”
outcome isolates (40%, 4/10) than clade A (15.7%, 14/89) (Fig. 2A and C). However, this
trend did not quite reach statistical signiﬁcance (P  0.08; Fisher’s exact test). Only 1/5
(20%) clade C isolates belonged to the “not-cured” outcome group, although the low
numbers of isolates precluded reliable statistical analysis (Fig. 2B and D). Furthermore,
clade B isolates also contained a higher percentage of moderately/strongly bioﬁlm-
forming isolates than clade A isolates (40% versus 31.5%) (Fig. 3A and C). In addition,
the majority of clade B isolates (80%) belonged to CC2, while clade A possessed only
60.7% CC2 isolates (data not shown).
Clinical outcome, bioﬁlm formation, and antibiotic resistance phenotypes were
homogeneous compared to the clonal frame (P  0.05). In addition, the permutation
test revealed a strong association between lineage and bioﬁlm formation (P  0.0001)
and resistance to methicillin (P  0.0002), quinolones (P  0.0055), erythromycin (P 
0.00001), clindamycin (P  0.00001), tetracycline (P  0.00001), trimethoprim-
sulfonamide (P  0.02), and fusidic acid (P  0.00001). However, there was no
association between lineage and outcome (P  0.09) or resistance to penicillin (P  1),
aminoglycosides (P  0.3798), fosfomycin (P  0.053), and rifampin (P  0.151).
DISCUSSION
S. epidermidis is a commensal microorganism that is also a frequent agent of ODRI
(6, 8, 16, 17). However, little is known about the impact that genotypic and phenotypic
features of the infecting pathogen can have on treatment outcome (3, 6, 8, 9). This
FIG 1 Percentages of genes present in the whole collection (black bars) and present in the two outcome groups.
Hatched bars, “cured” outcome; gray bars, “not-cured” outcome. *, statistically signiﬁcant (P  0.05).
TABLE 5 Association between the agr types and clinical outcome
Parameter
No. (%) of isolates with agr typea:
P valuebI II III
Clinical outcome 0.946
Not cured 7 (36.8) 5 (26.3) 7 (36.8)
Cured 33 (39.8) 19 (22.9) 31 (37.3)
Infection 0.002
Nonacute (chronic) 26 (35.1) 13 (17.6) 35 (47.3)
Acute 14 (50.0) 11 (39.3) 3 (10.7)
aTwo isolates not belonging to any of the 3 agr groups were excluded for statistical reasons.
bChi-square test.
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prospective study was designed to test the hypothesis that treatment outcome in
patients with S. epidermidis ODRI may be inﬂuenced by phenotypic or genotypic
features of the infecting pathogen. Against a background of scientiﬁc studies searching
for features that distinguish commensal from invasive isolates (3, 6, 8–11), or for host
factors that have an inﬂuence on patient outcome (8, 18), this study advances this line
of investigation by looking for bacteria-retained features that distinguish infections that
result in poor treatment outcome. After prospectively collecting 104 patients, with an
average 2-year follow-up (FUP), and subjecting infecting pathogens to genome se-
quencing and a number of phenotypic assays, we have identiﬁed a number of features
associated with poor treatment outcome. Those features include bioﬁlm formation,
TABLE 7 Relative overrepresentation (20% difference) of accessory genes in the “not-cured” outcome isolates
Locus Description of product
“Not cured” group
(n  19)
“Cured” group
(n  85)
Difference (%) between
“not cured” and
“cured” groups P value
No. of
isolates
Prevalence
(%)
No. of
isolates
Prevalence
(%)
SERP0915 IS256-like transposase 11 57.9 31 36.5 21.4 0.085
SERP1222 Transposase 9 47.4 16 18.8 28.5 0.008
SERP1586 Acetyltransferase, GNAT family 9 47.4 22 25.8 21.5 0.064
SERP2498 Cassette chromosome recombinase
A (CcrA)
17 89.5 56 65.8 23.6 0.042
SERP2499 Cassette chromosome recombinase
B (CcrB)
17 89.5 55 64.7 24.7 0.034
id1043_1239 Hypothetical protein 10 52.6 25 29.4 23.3 0.053
id1044_0888 Phage protein 8 42.1 15 17.6 24.5 0.02
id1044_0895 Phage antirepressor protein 8 42.1 17 20 22.1 0.041
id1044_1909 Antiseptic resistance protein QacA 17 89.5 53 62.4 27.1 0.023
id1044_2610 Unknown 8 42.1 15 17.6 24.5 0.02
id1048_0369 Replication-associated protein 11 57.9 29 34.1 23.7 0.054
id1632_0817 Zn-dependent hydroxyacylglutathione
hydrolase
14 73.7 44 51.7 21.9 0.082
TABLE 6MLST of the 104 clinical S. epidermidis isolates
STa CCb
No. (%) of isolates
Total “Cured” group “Not-cured” group
2 2 18 (17.3) 13 (72.2) 5 (27.8)
5 2 18 (17.3) 16 (88.9) 2 (11.1)
7 2 1 (1.0) 1 (100) 0 (0)
23 2 4 (3.9) 4 (100) 0 (0)
57 2 2 (1.9) 0 (0) 2 (100)
59 2 6 (5.8) 5 (83.3) 1 (16.7)
73 2 1 (1.0) 1 (100) 0 (0)
83 2 1 (1.0) 1 (100) 0 (0)
87 2 4 (3.9) 2 (50) 2 (50)
88 2 1 (1.0) 1 (100) 0 (0)
89 2 1 (1.0) 0 (0) 1 (100)
130 2 6 (5.8) 6 (100) 0 (0)
184 2 1 (1.0) 1 (100) 0 (0)
384 2 1 (1.0) 1 (100) 0 (0)
19 147 2 (1.9) 2 (100) 0 (0)
32 S32 2 (1.9) 2 (100) 0 (0)
110 S110 1 (1.0) 0 (0) 1 (100)
167 S167 1 (1.0) 1 (100) 0 (0)
297 S297 1 (1.0) 1 (100) 0 (0)
490 S490 1 (1.0) 1 (100) 0 (0)
528 S528 1 (1.0) 1 (100) 0 (0)
NAc NA 30 (28.9) 25 (83.3) 5 (16.7)
Total 104 (100) 85 19
aSequence types determined using the built-in MLST function of BIGSdb, linked with PubMLST databases.
bClonal complexes were obtained from previously described data (4).
cNA, possible truncation of a corresponding MLST locus at the end of a contig.
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aminoglycoside resistance, the cassette chromosome recombinase encoding genes
ccrA and ccrB, IS256-like and plasmid-borne qacA gene, as well as the bioﬁlm-associated
bhp gene.
Adhesion to and bioﬁlm formation upon biomaterial substrates are widely believed
to be the primary virulence factor enabling invasive S. epidermidis ODRI (6, 8, 16, 17, 19).
The data from our study supports this by revealing that a “not-cured” clinical outcome
was signiﬁcantly associated with an increased ability to form bioﬁlm in vitro (P 0.031).
Genomic analysis on the known bioﬁlm-associated genes, such as icaA, aap, bhp, or
embP, revealed that the only such gene found to be signiﬁcantly associated with a
“not-cured” outcome was bhp in the lower-extremity cohort (P  0.023). Interestingly,
bhp was most prevalent in the weakly bioﬁlm-forming isolates (52.7%) indicating that
its role may not be directly linked with bioﬁlm-forming ability, at least in vitro. bhp has
been reported to promote primary attachment to abiotic surfaces as well as intercel-
lular adhesion during bioﬁlm formation (20, 21). Thus, this protein might be important
for rapid attachment to the implant rather than the amount of bioﬁlm formed by the
isolate per se. A rapid attachment clearly may be signiﬁcant for early establishment of
bioﬁlm in vivo in “the race for the surface.” This may partially explain its association with
poor treatment outcome, despite the lack of association with in vitro bioﬁlm-forming
ability.
Antibiotic resistance is a second key challenge in treatment of ODRI. Previous
studies have suggested that methicillin resistance is associated with a worse treatment
FIG 2 Population structure of S. epidermidis isolates constructed from 123 core genes and implemented in ClonalFrame. (A and
B) All 104 isolates of the complete cohort (A) and all 70 isolates of the lower-extremity cohort (B) are labeled according to the
clinical follow-up (FUP) outcome: “not cured” (black circles) or “cured” (white circles). (C and D) Percent distributions of “cured”
and “not-cured” outcome in the three clades A, B, and C, showing the complete cohort (C) and the lower extremity cohort (D).
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outcome in staphylococcal ODRI (22–24), although a number of studies have provided
contrasting ﬁndings (8, 25, 26). Methicillin resistance is due to the mecA gene. In the
present study, resistance to methicillin showed a trend for a “not-cured” patient
outcome (P  0.082 based on phenotypic analysis and P  0.099 for presence of the
mecA gene), supporting previously reported trends (22–24). Furthermore, the chromo-
some recombinase A- and B-encoding genes ccrB and ccrA were signiﬁcantly more
prevalent in “not-cured” clinical-outcome isolates (89.5% versus 65.8% and 89.5%
versus 64.7%; P 0.042 and P 0.034, respectively). These two genes are responsible
for the chromosomal insertion of the genetic element called staphylococcal cas-
sette chromosome mec (SCCmec). The SCCmec mobile genetic island contains the
mec gene complex, including the methicillin resistance gene mecA. In this study,
91.8% of the ccrA/ccrB-positive isolates possessed the mecA gene, indicative for the
presence of the mobile element SCCmec. Of those 67 ccrA/ccrB/mecA-positive
isolates, only 2 were not phenotypically resistant to methicillin, which might be due
to mutations in the mecA gene. The 6 ccrA/ccrB-positive but mecA-negative isolates
were not phenotypically resistant to methicillin, indicative of an absent SCCmec
mobile element.
A second antibiotic class pertinent to the treatment of ODRI is the aminoglycosides
(including gentamicin and tobramycin), which are commonly used in antibiotic-loaded
bone cement (2, 16, 19, 27). Resistance to aminoglycosides in S. epidermidis isolated
from patients with ODRI typically ranges from 40 to 65% (19, 27). In this study, 39.4%
of the isolates were resistant to gentamicin/aminoglycoside, and we observed an
FIG 3 Population structure of S. epidermidis isolates constructed from 123 core genes and implemented in ClonalFrame. (A and
B) All 104 isolates of the complete cohort (A) and of the lower-extremity cohort (B) are labeled according to the ability to form
a bioﬁlm: bioﬁlm negative (white circles), weak bioﬁlm formers (gray circles), and moderate to strong bioﬁlm formers (black
circles). (C and D) Percent distribution of the strength of bioﬁlm formation in the three clades A, B, and C, showing the
complete cohort (C) and the lower-extremity cohort (D).
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association between the “not-cured” outcome and isolates being phenotypically resis-
tant to aminoglycosides (P  0.001). The majority of the aminoglycoside-resistant
isolates (65.8%) carried the aacA [aac(6=)-aph(2)] gene, which confers resistance to all
aminoglycosides. This gene was also observed in a higher prevalence in the “not-cured”
group (42.1%, versus 22.4% in “cured”; P 0.076). This correlates well with other studies
in terms of prevalence of the aacA [aac(6=)-aph(2)] gene among aminoglycoside-resistant
isolates, ranging between 40 and 92% (16, 28, 29), although how this impacted treatment
outcome was not described in these other studies.
Our data also revealed that the antiseptic (quaternary ammonium compound) qacA
gene was statistically more prevalent in the “not-cured” outcome group (P  0.023).
The qacA gene is a plasmid-borne gene (pSK1 family plasmids) that confers resistance
to antiseptics and disinfectants such as cetrimide, benzalkonium chloride, and chlo-
rhexidine (30–32). Our observation that the qacA gene was present in 67.3% of isolates
(89.5% of “not-cured” group isolates) within the complete cohort seems enriched
compared to that in other studies for clinical (47% to 52%) and commensal (25%) S.
epidermidis isolates (31, 32). Despite the relatively high presence in our collection and
a moderate number of “not-cured” isolates, there is some statistical signiﬁcance to
associate the presence of this gene with a poor treatment outcome. Qac proteins are
efﬂux pumps that protect bacteria not only from a variety of toxic substances but also
from ﬂuoroquinolones and -lactams (30–32). The acquisition of such a gene/plasmid,
possibly from antiseptic usage within the hospital, clearly provides the bacteria a
survival advantage, especially in a clinical environment. Such resistant pathogens
therefore not only are more difﬁcult to clean within the hospital environment but, as
we show, also are associated with a poor treatment outcome.
In addition, the IS256-like transposase was more frequently present in “not-cured”
clinical-outcome isolates than in “cured” outcome isolates (57.9% versus 36.5%; P 
0.085). Previous studies have described an association between the presence of the
IS256 element, the aac(6=)-aph(2[dprime]) gene (33, 34), the icaADBC operon, and the
ability to form bioﬁlm (11, 35, 36). Furthermore, IS256 has been suggested as a
molecular marker for the molecular typing and identiﬁcation of nosocomial, invasive S.
epidermidis isolates (9–11, 36). This study provides further evidence that IS256 not only
is “enriched” within invasive isolates but is also more prevalent in isolates with a poor
treatment outcome. The increased prevalence in the “not-cured” group indicates that
it is not a marker for infection but rather potentially is one for poor outcome; however,
this warrants further study with a larger set of isolates.
Previous genealogical reconstruction studies of S. epidermidis have shown that
isolates clustered into 3 phylogenetic clades (4, 6), which is consistent with the
observation in this study. To date, no study has associated genotypes with clinical
outcomes in ODRI. In this study, a higher number of “not-cured” outcome isolates were
found in clade B than in clades A and C. Clade B was also the lineage with the strongest
bioﬁlm-forming isolates. Harris et al. reported thick bioﬁlm being 20% more common
in CC2 isolates (6). In the present study, CC2 accounted for 80% of the 10 clade B
isolates, with 50% of them being responsible for moderate/strong bioﬁlm formation.
Furthermore, of these moderately/strongly bioﬁlm-forming CC2 clade B isolates, 75%
(3/4) resulted in a “not-cured” outcome. This emphasizes that clade B CC2 isolates
might be more likely to result in a poor clinical outcome. However, a greater number
of isolates should be analyzed in a prospective manner in order to conﬁrm this
observation and determine whether it may be a prognostic molecular marker for poor
treatment outcome.
A limitation of this study was that only a single S. epidermidis colony from each
patient was analyzed, although the infection could, at least in theory, be polyclonal. A
previous study has shown that only a minority of prosthetic joint infections (PJIs) (28.5%
[4/14 patients]) were due to polyclonal S. epidermidis strains (37). Any future studies
should consider analyzing several colonies from each patient. Furthermore, the mor-
phology of colonies was not recorded in the present study, and so we do not know how
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many, if any, small-colony variants (SCVs) were present in the current collection, but this
should be considered in future studies.
In general, SCVs present phenotypic features such as low growth rate and small
colony morphology (38–45). Additionally, SCVs are associated with increased bioﬁlm-
forming ability, antibiotic resistance, and ability to internalize and persist in osteoblasts,
all of which may contribute to prolonged treatment or even treatment failure (38–45).
In contrast to the case for S. aureus SCVs, very little information is available on S.
epidermidis SCVs (38, 46). Only recently has the pathogenesis of PJIs been associated
with S. epidermidis SCVs (38, 46, 47). Furthermore, SCV colonies from the same patient
showed difference in growth rate, colony size, and levels of gentamicin resistance
compared to each other (38). This highlights the importance of documenting and
analyzing SCVs, as they may inﬂuence treatment outcome.
Patients with a “not-cured” clinical outcome were more likely to have had multiple
revision surgeries than those with a with “cured” outcome (P  0.067), which is to be
expected as revision surgery is a standard intervention for failed treatment We have
considered the ﬁnal outcome to be “cured” or “not cured” at follow-up, regardless of
the treatment steps taken in the interim period. Therefore, even though multiple
revision surgeries occurred, if the patient was free of infection at FUP, we considered
the patient to be cured. Of course, the need for multiple revisions is possibly an
indicator that the infection was a greater challenge to treat; however, in a large patient
population such as this, there is often a need for multiple revision surgeries to advance
the healing of the fracture or replace the device, which may occur after infection has
cleared, and so such patients have also had multiple surgeries.
Overall, genome sequencing is not absolutely required to determine some of the
features identiﬁed in this study as being associated with poor outcome. For example,
routine antibiotic susceptibility testing and conventional in vitro bioﬁlm assays are
readily available to provide this information. Nevertheless, whole-genome sequencing
allowed us to test our hypothesis with greatest sensitivity and also identiﬁed features
that are less easily measurable in a clinical laboratory. Finally, it should be mentioned
that the treatment of ODRI is achieved by antibiotic therapy and surgical removal of
infected tissue. Therefore, the outcome of ODRI treatment will be inﬂuenced by these
factors in addition to the host defenses and not solely by the pathogen itself. The
factors identiﬁed in this study therefore require prospective validation in further studies
with larger patient cohorts in order to conﬁrm their value as prognostic markers for
ODRI treatment outcome.
MATERIALS AND METHODS
Ethics statement. Institutional Review Board approval was obtained from the local ethical commit-
tee Ethik-Kommission der Bayerischen Landesärztekammer under approval number 12063. The study
was registered with https://clinicaltrials.gov with identiﬁer NCT02640937. Only adult patients (18 years)
were included in this study, and all patients provided informed written consent prior to inclusion in the
study.
Staphylococcus epidermidis collection. This was a prospective study performed between November
2011 and September 2013 at the BGU Murnau, Germany, a level-one trauma center with a high volume,
70-bed unit for septic and reconstructive surgery. The phenotypic investigation of bioﬁlm formation by
a subgroup of these isolates has been previously described (8), although no genome sequence data for
these isolates have been previously published.
Inclusion criteria were treatment for a conﬁrmed S. epidermidis infection involving fracture ﬁxation
(FFI) or prosthetic joint infections (PJIs). Most of the primary surgeries for fracture ﬁxation or implantation
of an endoprosthesis were performed in other hospitals. In cases where the patient developed an
infection that was not treated/treatable at the primary center, the patient was transferred to the study
site which has a specialized unit for ODRI treatment. Bacterial growth in at least two biopsy specimens
collected at the site of interest in combination with nonunion, implant loosening/failure, or local and
systemic signs suggesting a surgical site infection were requirements for the diagnosis of ODRI, as per
hospital standards.
In the previously described clinical study, patient data were analyzed as a complete study cohort but
also as a cohort including only patients with infections associated with the lower limb (8). This is because
there are numerous outcome measures for the lower extremity that are not available for other
anatomical locations. These outcome measures include the lower-extremity functional score (LEFS) and
the short form 12 (SF-12) score, as well as leg length discrepancy (8). The remaining patients, not
included in the lower-extremity cohort, included patients with infections at other locations, such as
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upper extremity, pelvis, and spine (Table 1). At the ﬁrst surgical procedure after enrollment, bone biopsy
specimens were taken from the interface between implant and affected bone. Samples were placed in
a sterile container with thioglycolate liquid medium (bioMérieux, Hazelwood, MO, USA) and cultured for
10 days at 37°C. Any growth was inoculated onto a blood agar plate (bioMérieux, Hazelwood, MO, USA)
for further growth and subsequent identiﬁcation. All isolates were grown on tryptone soy agar (TSA)
(Oxoid, Pratteln, Switzerland) and incubated overnight at 37°C. A single colony was then taken and
resuspended in 1 ml tryptone soy broth (TSB) (Oxoid, Pratteln, Switzerland) containing 20% (vol/vol)
glycerol for long-term storage at 80°C. Although the colony morphology of culture-positive samples
was not described, we anticipate that SCV colonies had sufﬁcient time to emerge under standard
laboratory conditions and are not likely to have been missed in the clinical routine.
Clinical data collection. Clinical data were collected from each enrolled patient. The following
surgical parameters were documented: affected bone or joint, type of implant, time between implan-
tation of the device and onset of symptoms, and whether the fracture was open or closed (PJIs excluded).
Patients were assessed for treatment outcome after an average of 26 months of follow-up (FUP).
Patients were assigned to have had a “cured” or a “not-cured” outcome at FUP. Patients had a “cured”
clinical outcome if they were free of infection, surgical therapy and systemic antibiotic therapy had
ceased, and function of the affected joint or limb was restored. Patients were considered to have had a
“not-cured” clinical outcome if at least one of the above parameters was negative. Additional parameters
were documented, such as acute/nonacute (chronic) infection (cutoff for onset of symptoms, 6 weeks),
obesity (body mass index [BMI] of 30 kg/m2), diabetes, smoking, chronic immunosuppressive condi-
tions (diabetes mellitus, chronic alcoholism, Child’s class C cirrhosis, neoplasia, transplantation, AIDS, and
steroid medication), and whether multiple revision surgeries were required during treatment.
The clinical treatment strategies applied to these patients followed recent guidelines and recom-
mendations, including guidance on antimicrobial stewardship. Therefore, treatment strategies differed
between enrolled patients due to antibiotic resistance patterns, presence of implant (yes/no), and stage
of treatment. The use of antibiotic-loaded bone cement was not extracted from the patient records;
however, in all cases of infection with a gentamicin-resistant organism, any bone cement would have
been loaded with vancomycin as the preferred alternative. Whether an implant was removed or retained
was dependent upon the classiﬁcation of the infection and the health status of the patient. In chronic
infections, the implant was routinely removed in the ﬁrst revision surgery whenever possible. In general,
the implant was retained in acute infections if sufﬁcient debridement was possible.
Antibiotic susceptibility testing. Susceptibility to 28 antibiotics was determined using a Vitek2
machine (bioMérieux Vitek Inc., Hazelwood, MO, USA). The antibiotics tested were amikacin, ampicillin-
sulbactam, cefotaxime, cefoxitin, cefuroxime, ciproﬂoxacin, clindamycin, daptomycin, erythromycin,
fosfomycin, fusidic acid, gentamicin, levoﬂoxacin, linezolid, mezlocillin, moxiﬂoxacin, netilmicin, oﬂoxa-
cin, oxacillin, penicillin, piperacillin, rifampin, tetracycline, ticarcillin-clavulanate, tigecycline, tobramycin,
trimethoprim-sulfamethoxazole, and vancomycin. Multiple antibiotic resistance was deﬁned according to
the deﬁnitions of the European Committee of Antimicrobial Susceptibility Testing (EUCAST). Oxacillin
resistance was considered deﬁnitive for methicillin resistance status.
Bioﬁlm formation. Bioﬁlm formation was assayed as described previously (48, 49). Brieﬂy, overnight
cultures were grown in TSB and then subcultured in fresh TSB containing 1% glucose to approximately
1  106 CFU/ml. To achieve this, the bacterial density was adjusted to a target optical density (OD) of
known concentration using a Multiskan Go microplate reader (Thermo Scientiﬁc, Zürich, Switzerland). A
total of 200 l of the bacterial suspension was incubated in ﬂat-bottom 96-well tissue culture-treated
polystyrene microtiter plates (Nuclon; Nunc A/S, Denmark) for 24 h at 37°C. Plates were rinsed with
phosphate-buffered saline (PBS) (Sigma-Aldrich, Buchs, Switzerland) and stained with 150 l of Gram’s
crystal violet solution (Sigma-Aldrich, Buchs, Switzerland). The dye bound to the attached cells was
solubilized by addition of 150 l of 95% ethanol. Optical density was measured as absorbance at 595 nm
using the Multiskan Go microplate reader.
All isolates were tested in triplicate in three independent experiments. Each microtiter plate also
consisted of negative controls (wells without bacterial inoculation). The average OD value (ODa) was
calculated for each isolate and the negative control. The results were evaluated using the scale described
by Stepanovic et al. (49), whereby isolates may fall into the following four categories: bioﬁlm nonpro-
ducer, weak bioﬁlm producer, intermediate bioﬁlm producer, and strong bioﬁlm producer. Based on the
ODa values and the cutoff value (ODc), which is deﬁned as three standard deviations (SD) above the mean
OD of the negative control, ODc  average OD of negative control  (3  SD of negative control). The
strength of the bioﬁlm production of each isolate was calculated as follows: ODa  ODc  bioﬁlm
nonproducer, ODc  ODa  2  ODc  weak bioﬁlm producer, 2  ODc  ODa  4  ODc 
intermediate bioﬁlm producer, and 4  ODc  ODa  strong bioﬁlm producer. S. epidermidis reference
strain RP12 (ATCC 35983) was used as a control for strong bioﬁlm production.
Genome sequencing and assembly. S. epidermidis isolates were cultured on TSA plates at 37°C for
24 h. Single-colony cultures were harvested, resuspended in 3 ml of TSB medium to minimize clumping,
and incubated at 37°C with overnight shaking. Chromosomal DNA was extracted using a Qiagen QIAamp
DNA minikit (Qiagen, Hilden, Germany) following the manufacturer’s protocol, using 1 g/ml lysostaphin
(Sigma-Aldrich, Buchs, Switzerland) and 2 g/ml lysozyme (Sigma-Aldrich, Buchs, Switzerland) to facili-
tate cell lysis. DNA was sequenced at the Swansea University Genome Centre using a MiSeq benchtop
sequencer (Illumina, San Diego, CA, USA). Sequencing libraries were prepared using Nextera XT library
preparation kits (v2) and paired-end 250-bp reads generated with the MiSeq run kit (v2). Short-read data
were assembled using a de novo assembly algorithm within Velvet software (version 1.2.08) (50). Overall,
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the average number of contiguous sequences (contigs) for all 104 genomes sequenced in this study was
439, which gave rise to an average total assembled genome size of 2,436,856 bp.
Genomes are archived using a gene-by-gene approach for genome alignment and comparison
supported by the BLAST algorithm (51). A reference pan-genome was constructed from the clinical
isolate genomes (all collected as part of this study) and the reference S. epidermidis RP62A (ATCC 35984)
and ATCC 12228 genomes (52). Putative gene function was assigned to genes in the reference
pan-genome list using RAST (Rapid Annotations using Subsystem Technology) (53) and the SEED
database (54), which were cross-referenced with the S. epidermidis RP62A (ATCC 35984) and ATCC 12228
reference genomes before removing duplicate genes. The BLAST algorithm was used to scan all genomes
for gene orthologs at each locus in the reference pan-genome. An ortholog was deﬁned as a reciprocal
best hit of the sequence with70% nucleotide identity over at least 50% of the alignment length. MAFFT
software (55) was used to align gene orthologs on a gene-by-gene basis, and these data were
concatenated into contiguous sequence for each isolate genome, including gaps. A core genome of 123
genes was deﬁned based on gene presence in all isolates (100%).
Estimating genealogies. ClonalFrame infers the clonal relationship of bacteria and the chromo-
somal position of homologous recombination events that disrupt a clonal pattern of inheritance (56). A
stringent approach was used to estimate a reduced core genome for construction of a genealogy using
ClonalFrame (version 1.2) on concatenated sequences of 104 S. epidermidis genomes with 100,000
iterations, half of which were discarded as burn-in. Substitution mutation and recombination regions
were categorized from the output of ClonalFrame. The posterior probability of recombination and
substitution at each site is calculated by ClonalFrame, and recombination events were deﬁned with a
probability of recombination of more than 75%, reaching 95% at any one site. The trees were visualized
and annotated using MEGA6 (57).
Statistical analysis. Associations among and between the clinical parameters, bacterial phenotypes,
clades, and presence/absence of genes were analyzed statistically using the chi-square test, Fisher’s exact
test, the Cochran-Armitage trend test, or the Kruskal-Wallis test as appropriate. The chi-square test was
carried out to test the null hypothesis that the lineages are homogenous in their clinical outcome or
resistance phenotypes. Permutation tests were performed to test the null hypothesis that there was no
association between lineage and clinical outcome or resistance phenotype. Association between clinical
outcome or antimicrobial resistance and lineage in the observed data was summarized by an association
score. Statistical analyses were performed using SAS software (version 9.2; SAS, Cary, NC, USA) and SPSS
(version 10; IBM, USA), and the level of signiﬁcance was set at a P value of 0.05.
Data availability. Short reads are available from the NCBI Sequence Read Archive (SRA) associated
with BioProject no. PRJNA382527. Assembled genomes are also archived in the publicly accessible
Staphylococcal Bacterial Isolate Genome Sequence database (BIGSdb) (https://sheppardlab.com/
resources/).
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